EP1587559A1 - Dispositif d'apport automatique, entraine par des hydrogels, a caracteristique d'apport reglable, pour l'apport d'un milieu, en particulier d'insuline - Google Patents

Dispositif d'apport automatique, entraine par des hydrogels, a caracteristique d'apport reglable, pour l'apport d'un milieu, en particulier d'insuline

Info

Publication number
EP1587559A1
EP1587559A1 EP04701347A EP04701347A EP1587559A1 EP 1587559 A1 EP1587559 A1 EP 1587559A1 EP 04701347 A EP04701347 A EP 04701347A EP 04701347 A EP04701347 A EP 04701347A EP 1587559 A1 EP1587559 A1 EP 1587559A1
Authority
EP
European Patent Office
Prior art keywords
actuator
swelling agent
conveying device
automatic
pump
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04701347A
Other languages
German (de)
English (en)
Inventor
Andreas Richter
Christian Klenke
Karl-Friedrich Arndt
Gilbert Schiltges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tecpharma Licensing AG
Original Assignee
Disetronic Licensing AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disetronic Licensing AG filed Critical Disetronic Licensing AG
Publication of EP1587559A1 publication Critical patent/EP1587559A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
    • A61M5/14526—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons the piston being actuated by fluid pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M2005/14513—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons with secondary fluid driving or regulating the infusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body

Definitions

  • Automatic conveying device driven by hydrogels with adjustable discharge characteristic for conveying a medium, in particular insulin
  • the invention relates to an extracorporeal automatic fluidic delivery device based on hydrogel, in particular for the delivery of insulin, which has an extremely simple construction and small dimensions with a time and delivery characteristic that can be set by the user and is intended for single and / or repeated use.
  • Diabetes mellitus Administer the drug subcutaneously at a specific time at night.
  • the pump described here is installed and activated by the patient in the evening. It then automatically delivers the medication at the scheduled time without requiring any further action by the patient.
  • Diabetes mellitus can be considered as a special application in which there is an increased insulin requirement (dawn phenomenon) in the early morning hours. This high demand can be met by the pump with hydrogel actuator in a patient-specific manner without having to wake the patient.
  • the pump principle enables a constant small volume flow to be generated over a longer period of time. This is relevant in certain technical / medical applications.
  • the basic insulin requirement can be covered in type 2 diabetics. In contrast to the long-acting insulins available on the market, this ensures constant insulin delivery and intake from and within certain periods.
  • the pump principle can also implement complicated, programmable processes, such as those required for insulin pump therapy (CSU), in a simple and auxiliary energy-free manner.
  • CSU insulin pump therapy
  • An electromechanically operated injection pen is known from WO 93/16740. It has been developed for self-medication with liquid drugs or excipients to be injected. The expulsion of the liquid is made possible by the propulsion of a piston coupled to a spindle by means of motor power.
  • the disadvantage of these previously known devices is their complex structure and the dependence on an energy supply by means of a battery.
  • US 56 72167 also discloses an osmotically powered portable extracorporeal infusion pump. It consists of two storage bags, one contains the fluid to be pumped and the second bag contains the driving liquid. In turn, salination or osmotic forces from the concentration equalization of two liquids are used to convey fluids.
  • the infusion rate depends on the properties of the intermediate semipermeable membrane and must therefore be preset in the factory.
  • the pump is activated by a valve or by destroying a sealing layer. Pulsatile operation is only possible through the use of conventional energy-driven time-controlled pumps.
  • a trigger delay for osmotically operated pumps is disclosed in US4976966. It is achieved by pressing out a pump core with a semi-permeable membrane and an osmotic drive from an impermeable casing.
  • extracorporeal insulin pumps sometimes have a very wide range of setting functions and individually adaptable program sequences, they are very complicated in structure, which is why they are expensive and generally require auxiliary energy.
  • the described implantable drug delivery systems based on the principle of osmotic pumps are very simple.
  • the disadvantage of them is the implantation, which is always associated with high expenditure and risks, and the impossibility of setting the pump delivery characteristic on the patient side.
  • These facilities can also only cover the basic basic needs of the patient.
  • the object of the invention is to develop automatically acting extracorporeal pumps which have a simple structure, are inexpensive to manufacture, work with auxiliary energy and have the possibility of adjusting the delivery characteristics on the patient side.
  • the pumps should be characterized by a low susceptibility to faults.
  • hydrogels are the solid-state effect carriers with the largest usable volume change and work without auxiliary energy, ie they do not require any external energy supply, for example in the form of electrical quantities. These hydrogel properties make it possible to implement very simple pumps which, due to their design, have a predetermined delivery characteristic.
  • Modern insulin delivery systems demand an adjustable delivery characteristic that can be individually adjusted by a doctor or patient. On the one hand, this can be done by modifying the properties of the hydrogel actuator, but this usually requires complicated operation. On the other hand, the adjustability of the pump behavior can be realized through constructive measures. This option offers the advantage of simple operation.
  • ⁇ A - ⁇ (gel) - ⁇ A (environment) can be set. This equation initially states that until an equilibrium state is reached, the gel increases its volume by swelling agent absorption.
  • the first possibility of influencing results from the chemical potential of the solvent in the hydrogel ⁇ A (gel). This is a material-specific quantity, which is determined by the chemical composition, cross-link density, etc.
  • an actuator made of a hydrogel with the desired swelling characteristics must be used at the actuator location of a pump, which e.g. can happen in cartridge, tablet or similar form.
  • this possibility is associated with a rather complicated operating process.
  • the variation of the chemical potential of the solvent in the environment ⁇ offers further possibilities for subsequent adjustment of the source kinetics or actuator dynamics. This can be done very simply by providing the swelling agent in a metered manner. In terms of construction, this is possible by adjusting the cross section of the swelling agent feed.
  • the potential difference ⁇ A between the gel and the environment can also be influenced by a pressure which counteracts the swelling pressure.
  • a pressure can be realized constructively by means of a spring element or by an element which generates a force which counteracts the swelling process as a result of friction. Since the swelling process of hydrogels is differentially controlled, the actuator dynamics can also be determined by the dimension and macroscopic structure of the hydrogel actuator. The relaxation time constant determining the temporal swelling process is related
  • the equation states that in addition to the cooperative diffusion coefficient describing the swelling agent-hydrogel system, the smallest characteristic dimension of the hydrogel actuator determines its time behavior via a quadratic proportionality. Small hydrogel structures are therefore desirable for short swelling times and large hydrogel structures for long swelling times.
  • pulsatile characteristic curves can be realized through series-connected actuator segments with different source properties.
  • material segments made of substances that dissolve in a defined time due to the action of solvents can be used. After the dissolving process, the next hydrogel segment that has an active effect is activated by the action of a swelling agent.
  • One setting option is the user-side compilation of the actuator from the required segments.
  • the variation of the swelling agent mixture by the user can also be used, for example by using different solvent reservoirs in the required order be connected to the swelling agent reservoir and the resulting dynamic swelling agent mixture adjusts the actuator dynamics according to the requirements.
  • the application of different counterforces can be used in the necessary order. If the counterforces are applied, for example, by friction pairings of bores and round rod segments with defined friction coefficients, the counterforce can be changed by varying the inner diameter (bore diameter), since the outer diameter of the round rod segment is constant. The duration of action of the respective counterforce can be determined by the guide length of the round rod segment in the specific inner diameter.
  • Another option for setting the characteristic curve is the use of hydraulic translation mechanisms. By varying the cross section of the actuator chamber in its source or effective direction, both its force effect and its travel can be changed according to the principle of preservation of work.
  • the pump characteristic curve can also be changed by varying the cross section of the swelling agent supply. If the cross-section is narrowed, the pump delivers slowly, if it is expanded, the actuator can swell more quickly and the pump has a higher delivery rate. If the swelling agent supply is stopped, the pump function is interrupted. This can also be used as an emergency stop function.
  • An adjustable time delay from pump commissioning to the start of actual delivery can also be achieved using various methods.
  • dissolvable swelling agent barriers can in turn be used in the feed path; their delay time can be determined by the material used and its effective effective thickness.
  • An idle travel of the hydrogel actuator can be used as another setting principle for the time delay. After activation, it must first expand in an actuator-ineffective cavity in order to then be able to act on the medication reservoir. In this case, the time delay is a function of the idle travel to be completed.
  • the swelling agent is not provided by the pump environment (with implanted pens, the body fluid is used as a swelling agent).
  • a swelling agent reservoir must therefore be integrated in the pump.
  • the swelling agent reservoir In order to ensure that the pump function is independent of the position of the applicator (i.e. the swelling agent must always be available), the swelling agent reservoir must be pressurized with such an overpressure that even in the worst case scenario there is a pressure difference driving the swelling agent into the actuator chamber.
  • the hydrostatic excess pressure required in the swelling agent reservoir can e.g. can be realized by a prestressed elastic covering or by an acting spring.
  • hydrogel-based pumps are usually only designed for single use. In order to be able to use pumps for multiple use, the drive must be able to be reset to its initial state. This is possible through the use of smart hydrogels or swellable polymer networks with discontinuous phase transition behavior. These smart hydrogels have the property of reacting in their phase transition area to small changes in special environmental sizes with pronounced volume changes. For example, hydrogels with a so-called lower critical solution temperature characteristic are known which swell at temperatures below their phase transition temperature and swell above. For example, the homopolymer poly (N-isopropylacrylamide) has a phase transition temperature of approximately 33 ° C. in an aqueous environment.
  • the position of this phase transition can be adjusted almost anywhere between 5 and 50 ° C. by copolymerization and also by variation of the swelling agent composition.
  • a pump user can not only sterilize the pump by placing it in a heat sterilizer or in boiling water, but also reinstalling the pump drive from the smart hydrogel the initial resp. reset the swollen state so that it can be reused afterwards.
  • FIG. 2 A principle for realizing the time delay mechanism for a
  • FIG. 3 the mode of action of a frictional force counteracting the swelling force
  • FIG. 4 the delivery characteristic of a pump according to FIG. 1 Figure 5
  • FIG. 5a illustrates the dialing system of the automatic pump of Figure
  • Figure 6a The assembly for mechanical programming of the pump according to Figure 6.
  • the pump according to FIG. 1 has a time delay which can be set by the user and is designed in particular for the treatment of the down phenomenon. It promotes the required amount of active ingredient within a certain period of time after the delay. It enables the user to set the necessary delay before going to bed, to apply and to activate the pump. After the set time, the pump automatically pumps the active ingredient so that the user can sleep through the night.
  • the pump according to FIG. 1 consists of a pump body 1, which initially ensures the mechanical functional reliability and defines the installation space for the further functional elements.
  • an extracorporeal pump cannot obtain the swelling agent from its surroundings in the form of body fluid.
  • the pump therefore contains a swelling agent reservoir 4 in which the swelling agent is made available.
  • the swelling agent reservoir can have a solid, dimensionally stable envelope or an elastic envelope.
  • the condition of a dimensionally stable casing, the function of which can also be carried out by the pump housing 1, is an executable and sealing plug, via which the excess pressure can be coupled into the swelling agent. If a rubber-elastic material is used for an elastic covering, for example a latex or silicone molded part, the hydrostatic excess pressure can be applied in order to implement the position-independent provision of swelling agent in terms of functionality by the elastic restoring force of the covering.
  • the pump trigger 7 must be actuated to start up the pump. In the arrangement shown, it can work according to two principles. If it is equipped with a destructive element, for example a hook, it destroys the covering of the swelling agent reservoir 4, so that the swelling agent can reach the actuator chamber 3 through the swelling agent supply element 7a. If it is designed as a shut-off valve, it creates a connection between the swelling agent reservoir 4 and the actuator chamber 3 when actuated. In addition to its function as a trigger seat, the swelling agent supply element 7a has the task of providing the swelling agent in a defined amount to the gel actuator 2 after the pump has been started up. This feed rate can be determined constructively via the effective feed cross-section through which the flow can flow and the size of the hydrostatic excess pressure of the swelling agent reservoir.
  • the supply cross-section can be determined, for example, by the diameter and the number of bores in the source / feed element 7a or by the use of porous materials or membranes. Since porous or membrane materials with defined permeability and small tolerances of almost any size order are commercially available, their use in the source means 7a offers itself.
  • the actuator material 2 begins to swell from a swellable polymer network as a result of swelling agent absorption. Because of the only available degree of freedom, the actuator 2 will now extend unidirectionally in the direction of the active substance reservoir and the retarding disk.
  • the actuator chamber 3 shown in Figure 1 has a flexible envelope, e.g. in the form of latex or polyethylene film material.
  • a flexible envelope e.g. in the form of latex or polyethylene film material.
  • an elastic version e.g. rubber-elastic latex covering
  • the actuator chamber itself can also have a rigid casing, as is the case, for example, when the actuator chamber walls are formed by the pump housing 1, the firmly seated swelling agent supply element 7a and the movable retardation disk 14.
  • the actuator material 2 itself consists of swellable polymer networks.
  • Purchasable materials that are used, for example, as superabsorbers appear to be particularly suitable. In addition to a low price, they are characterized by very good actuator properties, high volume expansion and good constancy of properties.
  • the most important actuator materials are polymers based on acrylic acid, e.g. anionic polyacrylates such as Na polyacrylate.
  • anionic polyacrylates such as Na polyacrylate.
  • other swellable polymer networks with the required properties can also be used. Since this field is very large, only a few derivative classes are listed without any claim to completeness: acrylamides, vinyl alcohols, urethanes, vinyl ethers, cellulose, gelatin.
  • the actuator material and its macroscopic structure in interaction with the available swelling agent, its quantity per unit of time and the forces opposing the actuator, largely determine the pump characteristic.
  • Three material parameters are relevant for the actuator properties.
  • the chemical composition of the polymer network determines the realizable framework of the actuator properties as well as the swelling behavior over time.
  • the crosslinking conditions via the crosslinking density and the microscopic structure (eg homogeneous or porous polymer network), the behavior over time, the maximum degree of swelling that can be achieved and the possible swelling pressure can also be determined.
  • the third material parameter for setting the actuator properties is its macroscopic structure.
  • the actuator material is usually not filled into the actuator chamber 3 as a whole body, but in particle form.
  • the particle size and the particle size distribution determine the maximum possible actuator stroke, the temporal behavior and the repeatability of the actuator behavior. This effect is caused by the ratio of the total actuator volume to the dry volume of the polymer network. If the effective empty space between the individual particles is large, the particles must use a considerable part of their swelling process to fill these cavities, so that both the maximum possible actuator stroke and the effective swelling time of the actuator decrease.
  • the particle size distribution influences the repeatability of the actuator behavior. If it is chosen too wide, the temporal behavior and the actuator stroke will vary greatly.
  • the corresponding particle sizes and particle size distributions can be obtained very easily by grinding the starting material and then sifting with test sieves. Characteristic particle sizes are between 50 ⁇ m and 1500 ⁇ m, the particle size distributions should not exceed the limits of + 100 ⁇ m.
  • the actuator 2 At the beginning of the unidirectional expansion of the gel actuator 2 as a result of the action of swelling agent, it will reach the deceleration disk 14. This component is not of fundamental importance for the pump, but it serves to reduce the pump penbauner.
  • the mode of operation of the deceleration disk is illustrated in FIG. 3. If the actuator 2 only has to overcome the force F during the swelling process, it will set its swelling balance characteristic of F after a certain time. However, if it works against a force of size 2F, such as exists due to a friction pairing (press or transition fit) of the retarding disk 14 and pump housing 1, the actuator will achieve its swelling balance characteristic of 2F with a smaller actuator stroke at approximately the same time. Subsequent relief on F, as occurs, for example, when the deceleration disk 14 is moved from the friction or press-fit area into a play-fit area, causes the swelling process to be restarted to the characteristic swelling balance of the force F.
  • FIGS. 2a and 2b The principle of the time delay between pump start-up and the start of active substance delivery is illustrated by FIGS. 2a and 2b.
  • Figure 2a the initial state of the pump is shown shortly after activating the actuator 2.
  • the actuator 2 will now push the delay disk 14, if it is present, and the active substance reservoir 5, if this is movable, in the direction of the opener tapping 10 over a length lvz until the end position of the time delay process according to FIG. 2b is reached which the drug reservoir 5 is pressed against the opener 10.
  • the time delay is a function of the length lvz. The larger the lvz, the longer it is. Time Delay.
  • the pump user can set the time delay by changing the length lvz by turning the adjusting screw 11, which is fastened to the pump housing 1 with a thread.
  • a corresponding time scale is advantageously located on the pump housing 1 and a marking on the adjusting screw 11.
  • the relationship time delay - lvz can be assumed to be linear if the actuator 2 is oversized and thus only the practically linear increase in the actuator characteristic curve (see FIG. 3) is used. This relationship is an optimization parameter that must be experimentally adapted to the respective funding task.
  • the drug reservoir 5 After passing through the time delay unit, the drug reservoir 5, which until then has been sterile closed, is pressed by the actuator 2 against the opener piercing 10 in such a way that the drug reservoir envelope is pierced by it and thus opened. With the remaining actuator stroke, the active substance reservoir, which in the case shown has an elastic covering, is now emptied via the active substance outlet 8 in a certain time.
  • a movable member for example a stopper, must be present on the actuator side and a pierceable membrane on the puncture side.
  • Is protection against excessive release of active substances required e.g. can occur with mechanical deformation of an elastic pump housing 1, a flow restriction device 9 in the form of ball valves (see Figure 1), flap valves or the like. place easily between tapping 10 and agent outlet 8.
  • These valves are pressure differential controlled. They are open at low pressure differences or flow velocities, while when certain pressure differences or flow velocities are exceeded they close between the inlet and outlet.
  • FIG. 1 An example of an application for the pump shown in FIG. 1 will be presented with reference to FIG.
  • the pump used for the delivery characteristic shown in FIG. 4 has the structure shown in FIG. 1.
  • FIG. 5 pumps are to be presented which are designed for continuous delivery with a defined amount of active ingredient delivered per unit of time over a specific, adjustable period of time.
  • the pump initially has the same main components as that according to FIG. 1, but without a time delay unit, since this is unnecessary for the application now described. It is put into operation by actuating the pump trigger 7 by guiding the force flow generated by the user via the fully compressed biasing spring 6 to the swelling agent reservoir 4 in such a way that the force required to pierce the actuator-side conversion of the swelling agent reservoir 4 with the tapping 13 is exceeded.
  • the swelling agent can now reach actuator 2 through piercing needle 13.
  • the position independence of the source material supply is again ensured by the pretensioning device 6 by means of hydrostatic overpressure.
  • the swelling agent must pass through the dial of the effective supply cross section 17.
  • the element 17 has three concentrically arranged areas with different supply cross sections 17a, b, c (see also FIG. 5a). Since the selection disk 17 is rotatably mounted, the user can select an appropriate supply cross-section and thus determine the amount of swelling agent available per unit of time. This enables him to determine the delivery rate of the pump, i.e. how much active ingredient should be delivered per unit of time.
  • the time-dosed swelling agent reaches the selection disk 12, which is provided, for example, with three functional bores which are placed in accordance with the concentric arrangement of the supply cross sections of the element 17.
  • these functional bores there are, for example, three different actuator segments 2a, 2b, 2c (see FIG. 5a), which can contain both a different actuator material composition and different fill quantities.
  • the actuator 2a, b, c to be activated the maximum total volume that can be conveyed can be set, for example, via the actuator-effective filling quantity of actuator material.
  • a fine adjustment of the actuator dynamics etc. is also conceivable.
  • Disc system and their combination the same effect of continuous funding with a defined amount of active ingredient delivery per unit of time can be achieved over a certain, adjustable period.
  • the electoral system can also be implemented differently than described here.
  • the swelling agent metered in time by the selection element 17 now activates the actuator segment selected with the selection disk 12, e.g. 2a. This now presses the drug reservoir 5, which is also concentrically mounted, and presses it until it pierces the tapping 10.
  • the tapping 10 now opens the drug reservoir 5, which was previously sterile closed, and enables the drug to flow out through the drug outlet 8.
  • the remaining actuator stroke drives the drug up to the amount specified by the actuator material or actuator fill quantity.
  • a suitable combination of several selection elements can be used to implement an automatically delivering pump with an adjustable, pulsatile delivery characteristic.
  • Such a pump is shown by way of example in FIG. 6.
  • the functional sequence is the same as that described for the configuration according to FIG. 5.
  • the swelling agent must pass through a defined feed cross-section, which in turn can be designed as a dial, or as shown in FIG. 6a, in the form of separating membranes 16a, b, c as part of the dial 12a.
  • the swelling agent then reaches the actuator segment 2a, b or c selected with the selection disk 12a, which now begins to swell.
  • the swelling agent front completely penetrates the selected actuator segment of the dial 12a and now reaches the actuator segment connected by the dial 12b, which can have different temporal-actuator properties than that of 12a.
  • the same process takes place with the dial 12c.
  • the respective actuator stroke forces the downstream actuator segments out of their position in the dials.
  • the dialing Disks 12a, b, c only the combination of individual conveyor sections and their timing is determined.
  • the functional bores 15a, b, c of the dials 12 can contain, in addition to actuator material, also material that is not actuatively effective, but that transmits the actuator stroke and the swelling agent front. This is particularly relevant for interruptions in funding.
  • the resulting time-defined actuator stroke now opens the active substance reservoir 5 in the form already described in FIG. 5 and drives the active substance pulsatile out of the pump via the active substance outlet 8.
  • This mechanically programmable pump can also be based exclusively or in combination on the other possibilities of influencing the pump characteristics already described.

Landscapes

  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Fluid Mechanics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • External Artificial Organs (AREA)

Abstract

Dispositif d'apport automatique extracorporel fluidique, à base d'hydrogel, qui possède une structure simple et une taille minime, ainsi qu'une caractéristique d'apport et de durée réglable par l'utilisateur, ledit dispositif étant destiné à un usage unique et / ou multiple.
EP04701347A 2003-01-13 2004-01-12 Dispositif d'apport automatique, entraine par des hydrogels, a caracteristique d'apport reglable, pour l'apport d'un milieu, en particulier d'insuline Withdrawn EP1587559A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10300896 2003-01-13
DE10300896A DE10300896A1 (de) 2003-01-13 2003-01-13 Automatische, von Hydrogelen getriebene Fördereinrichtung mit einstellbarer Abgabecharakteristik zum Fördern eines Mediums, insbesondere Insulin
PCT/EP2004/000138 WO2004062714A1 (fr) 2003-01-13 2004-01-12 Dispositif d'apport automatique, entraine par des hydrogels, a caracteristique d'apport reglable, pour l'apport d'un milieu, en particulier d'insuline

Publications (1)

Publication Number Publication Date
EP1587559A1 true EP1587559A1 (fr) 2005-10-26

Family

ID=32519876

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04701347A Withdrawn EP1587559A1 (fr) 2003-01-13 2004-01-12 Dispositif d'apport automatique, entraine par des hydrogels, a caracteristique d'apport reglable, pour l'apport d'un milieu, en particulier d'insuline

Country Status (6)

Country Link
US (1) US7479135B2 (fr)
EP (1) EP1587559A1 (fr)
JP (1) JP2006514871A (fr)
CA (1) CA2511565A1 (fr)
DE (1) DE10300896A1 (fr)
WO (1) WO2004062714A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782852A1 (fr) * 2005-11-04 2007-05-09 F.Hoffmann-La Roche Ag Dispositif pour délivrer automatiquement d'un médicament liquide dans le corps d'un patient
DE102006025095B4 (de) * 2006-05-24 2017-07-13 Technische Universität Dresden Hydrogelbasierte Einrichtung
US20080177149A1 (en) * 2006-06-16 2008-07-24 Stefan Weinert System and method for collecting patient information from which diabetes therapy may be determined
DE102006040678A1 (de) * 2006-08-30 2008-03-20 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Produkts
US8202267B2 (en) * 2006-10-10 2012-06-19 Medsolve Technologies, Inc. Method and apparatus for infusing liquid to a body
DE102006051535A1 (de) * 2006-10-27 2008-12-18 Andreas Dr. Richter Automatischer Mikrofluidik-Prozessor
US20080161754A1 (en) * 2006-12-29 2008-07-03 Medsolve Technologies, Inc. Method and apparatus for infusing liquid to a body
ATE494919T1 (de) 2007-11-13 2011-01-15 Acuros Gmbh Osmotische pumpe
US8708961B2 (en) * 2008-01-28 2014-04-29 Medsolve Technologies, Inc. Apparatus for infusing liquid to a body
US8986250B2 (en) * 2008-08-01 2015-03-24 Wisconsin Alumni Research Foundation Drug delivery platform utilizing hydrogel pumping mechanism
US8328757B2 (en) * 2010-01-08 2012-12-11 Wisconsin Alumni Research Foundation Bladder arrangement for microneedle-based drug delivery device
DE102010030502A1 (de) 2010-06-24 2011-12-29 HSG-IMIT-Institut für Mikro- und Informationstechnologie Quellstoffaktor und Fördereinrichtung, insbesonder für eine medizinische Wirksubstanz
DE102010030504A1 (de) 2010-06-24 2011-12-29 HSG-IMIT-Institut für Mikro- und Informationstechnologie Quellstoffaktor mit elektrisch angetriebener fluidischer Transportvorrichtung
US8565895B2 (en) * 2010-09-23 2013-10-22 Biotronik Se & Co. Kg Implantable electrode lead and hydrogel sensor
US11173244B2 (en) 2011-09-02 2021-11-16 Unl Holdings Llc Drive mechanism for drug delivery pumps with integrated status indication
EP2731642B1 (fr) 2011-09-02 2018-09-19 UNL Holdings LLC Mécanisme d'insertion pour une pompe d'administration de médicaments
US9707335B2 (en) 2011-09-02 2017-07-18 Unitract Syringe Pty Ltd Drive mechanism for drug delivery pumps with integrated status indication
CA2845367C (fr) 2011-09-02 2019-09-17 Unitract Syringe Pty Ltd Mecanisme d'entrainement pour des pompes d'administration de medicaments a indication integree de l'etat
US9814832B2 (en) 2011-09-02 2017-11-14 Unl Holdings Llc Drive mechanism for drug delivery pumps with integrated status indication
IN2014CN02737A (fr) * 2011-09-13 2015-07-03 Unitract Syringe Pty Ltd
KR20140135736A (ko) 2012-03-12 2014-11-26 유니트랙트 시린지 피티와이 엘티디 무균 유체 경로 조립체용 충전-완료 카트리지 및 충전-완료 카트리지를 포함하는 약물 전달 장치
DK2890433T3 (da) 2012-08-29 2020-01-27 Unl Holdings Llc Drivmekanisme med kontrolleret administation til lægemiddeladministrationspumper
USD745142S1 (en) 2012-08-30 2015-12-08 Unitract Syringe Pty Ltd Drug delivery pump
USD723157S1 (en) 2013-03-12 2015-02-24 Unitract Syringe Pty Ltd Drug delivery pump
JP6273655B2 (ja) 2013-01-25 2018-02-07 ユーエヌエル ホールディングス エルエルシーＵＮＬ Ｈｏｌｄｉｎｇｓ ＬＬＣ 一体化された流体経路接続部及び薬剤容器
JP6496315B2 (ja) 2013-08-23 2019-04-03 ユニトラクト シリンジ プロプライエタリイ リミテッドＵｎｉｔｒａｃｔ Ｓｙｒｉｎｇｅ Ｐｔｙ Ｌｔｄ 薬剤送り出しポンプ用の一体形穿刺可能シール流体経路連結手段及び薬剤容器
EP3200851A1 (fr) 2014-09-29 2017-08-09 Unitract Syringe Pty Ltd Mécanisme d'insertion d'aiguille rigide pour pompe d'administration de médicaments
TWD174176S (zh) 2014-11-07 2016-03-01 優尼翠克注射器有限公司 給藥裝置之部分（二）
US20170237275A1 (en) * 2015-01-26 2017-08-17 Panasonic Intellectual Property Management Co., Ltd. Electricity storage device
USD794770S1 (en) 2015-06-26 2017-08-15 Unitract Syringe Pty Ltd Drug delivery pump
USD794771S1 (en) 2015-07-10 2017-08-15 Unitract Syringe Pty Ltd. Drug delivery pump
DE102016200211A1 (de) * 2016-01-11 2017-07-13 Raumedic Ag Medikamentenabgabe-Vorrichtung und eine Medikamentenabgabe-Baugruppe
KR20190039972A (ko) 2016-08-08 2019-04-16 유엔엘 홀딩스 엘엘씨 약물 전달 장치 및 유체 유로 연결 방법
TW201811385A (zh) 2016-08-30 2018-04-01 澳洲商優尼揣克注射器有限公司 用於藥物遞送泵之受控遞送驅動機構

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474575A (en) * 1982-02-01 1984-10-02 Alza Corporation Self-driven pump assembly and method of operation
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
MX9305545A (es) * 1992-09-09 1994-06-30 Alza Corp Dispositivo dispensador impulsado por fluido.
TW245642B (fr) * 1992-09-29 1995-04-21 Alza Corp
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5869078A (en) * 1996-04-25 1999-02-09 Medtronic Inc. Implantable variable permeability drug infusion techniques
US5798114A (en) * 1996-04-30 1998-08-25 Medtronic Incorporated Refillable body powered drug delivery techniques
GB2347081A (en) * 1999-02-23 2000-08-30 William Leslie Porter Device for supplying a beneficial substance to an animal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004062714A1 *

Also Published As

Publication number Publication date
US20060116664A1 (en) 2006-06-01
JP2006514871A (ja) 2006-05-18
DE10300896A1 (de) 2004-07-22
WO2004062714A1 (fr) 2004-07-29
US7479135B2 (en) 2009-01-20
CA2511565A1 (fr) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2004062714A1 (fr) Dispositif d'apport automatique, entraine par des hydrogels, a caracteristique d'apport reglable, pour l'apport d'un milieu, en particulier d'insuline
DE2916835C2 (fr)
DE69921809T2 (de) Von Patienten gesteuerte Medikamentenverabreichungsvorrichtungen
EP0389477B1 (fr) Dispositif d'injection utilise avec une ampoule deformable
EP0401515B1 (fr) Dispositif implantable pour l'administration dosée de médicaments dans le corps humain
DE60110236T2 (de) Vorrichtung zum verabreichen einer flüssigkeit mit einem konstanten volumenstrom und einem knopf für eine einstellbare bolusabgabe
CH699723B1 (de) Vorrichtung zur Verabreichung eines fluiden Produkts.
EP3012600B1 (fr) Dispositif de dosage pour un système d'infusion
US7935079B2 (en) Troubleshooting accelerator system for implantable drug delivery pumps
EP1782852A1 (fr) Dispositif pour délivrer automatiquement d'un médicament liquide dans le corps d'un patient
DE69928012T2 (de) Injektionsvorrichtung
EP2303367A1 (fr) Dispositif présentant au moins une chambre destinée à contenir un médicament ou un volume d'échantillon
EP1523354B1 (fr) Dispositif d'administration a entrainement osmotique
DE10102814A1 (de) Medikamentenabgabepumpe mit isolierter, hydraulischer Bemessung
EP0960626B1 (fr) Dispositif implantable pour l'application d'une solution et dispositif d'actionnement d'une seringue pour remplir le dispositif implantable
DE602004003168T2 (de) Impantierbares Gerät zur Verabreichung von Medikamenten mit einer Kapillaröffnung für geringe Durchflussraten
EP1944672A2 (fr) Pompe à liquide mécanique
EP1513572A1 (fr) Dispositif pour l'injection sans aiguille d'une substance dans un tissu d'un etre humain ou d'un animal, dispositif pour creer sans aiguille un canal d'injection et procede pour l'injection d'une substance dans ledit tissu
DE60022394T2 (de) Osmotisches system zur wirkstoffverabreichung
CH660973A5 (de) Infusionseinrichtung.
DE102006025095B4 (de) Hydrogelbasierte Einrichtung
DE102009017662B4 (de) Elektronische Pille zur steuerbaren Abgabe einer Substanz, insbesondere eines Medikaments, in einem menschlichen oder tierischen Körper
DE3600217A1 (de) Geraet zur soforthilfe bei herzanfaellen
WO2002087665A1 (fr) Pompe pour administrer des medicaments de façon dosee et regulee dans le temps
DD247151A1 (de) Anordnung zur beseitigung des restinfusats bei dampfdruckgetriebenen infusionspumpen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SCHILTGES, GILBERT

Inventor name: ARNDT, KARL-FRIEDRICH

Inventor name: KLENKE, CHRISTIAN

Inventor name: RICHTER, ANDREAS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100803